Menu
Not yet recruiting NCT07605182

Effectiveness of Live Motile Sperm Sorting Device on IVF Outcomes in Advanced Paternal Age

No phase Interventional Male Infertility Advanced Paternal Age Assisted Reproductive Technology

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: LensHooke® CA0 sperm sorting device, Density Gradient Centrifugation.
Who it may be relevant to
Registry conditions: Male Infertility, Advanced Paternal Age, Assisted Reproductive Technology. Basic parameters: from 40 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Vietnam
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Evaluation of the Effectiveness of Live Motile Sperm Sorting Device on In Vitro Fertilization Outcomes in Advanced Paternal Age Group

Overview

Male infertility contributes significantly to infertility, particularly in advanced paternal age men where sperm DNA fragmentation is increased. Conventional density gradient centrifugation may induce oxidative stress and sperm damage. LensHooke® CA0 is a centrifugation-free sperm sorting device designed to improve sperm quality and reduce DNA fragmentation. This prospective comparative study evaluates the effectiveness of CA0 versus conventional density gradient centrifugation on post-processing sperm quality, DNA fragmentation index, blastocyst formation, euploid embryo rate, and clinical pregnancy outcomes in IVF/ICSI cycles involving men aged 40 years or older

Detailed description

Male infertility contributes to approximately 50% of all infertility cases. One of the essential steps in assisted reproductive technology (ART) is sperm preparation, which aims to select motile, morphologically normal spermatozoa with minimal DNA damage. However, conventional sperm preparation techniques involving centrifugation may increase oxidative stress and sperm DNA fragmentation. The live motile sperm sorting device LensHooke® CA0 has been proposed as an alternative to traditional density gradient centrifugation (DGC), aiming to reduce sperm damage and potentially improve IVF outcomes.

LensHooke® CA0 offers several advantages: it avoids centrifugation and the mechanical stress associated with it; optimally reduces the DNA fragmentation index (DFI); minimizes the risk of premature acrosome reaction (AR); is suitable for both normozoospermic and non-normozoospermic semen samples; simplifies workflow (only three pipetting steps required: loading, medium addition, and recovery); and ensures a high degree of standardization, reducing inter-technician variability.

Moreover, paternal age is an important factor influencing sperm quality and fertility potential. Studies have demonstrated that men over 40 years of age exhibit higher sperm DNA fragmentation rates, increased morphological and motility abnormalities, and are associated with a higher incidence of embryonic chromosomal abnormalities and reduced live birth rates. Therefore, this population particularly requires optimized sperm selection methods to improve IVF/ICSI outcomes.

This study aims to evaluate the clinical value of this device through two primary objectives:

1. To compare sperm quality post-processing and the DNA fragmentation index between the CA0 method and the conventional DGC method in advanced paternal age group. 2. To compare the rates of blastocyst formation, euploid embryos, and clinical pregnancy between the two sperm preparation techniques in advanced paternal age group.

Interventions

  • Device LensHooke® CA0 sperm sorting device
    Sperm will be processed using the CA0 device by loading 1.0 mL of semen into the lower chamber and adding 0.9 mL of pre-equilibrated sperm washing medium into the upper chamber. The device is incubated at 37 °C for a minimum of 30 minutes, followed by aspirating 0.5 mL of recovered sperm suspension for ICSI.
  • Device Density Gradient Centrifugation
    Sperm will be prepared by layering 1 mL of 45% medium and 1 mL of 90% medium with 1 mL of semen sample. This is followed by a first centrifugation at 1500 rpm for 15 minutes, a wash step using 2 mL G-IVF plus medium, and a second centrifugation at 1200 rpm for 10 minutes to retain 0.5 mL of the sperm suspension.

Primary outcome measures

  • Clinical Pregnancy Rate after single embryo transfer [Time frame: 4 to 6 weeks after embryo transfer]
Secondary outcome measures (3)
  • Post-processing sperm DNA fragmentation index (DFI, %) [Time frame: Immediately after sperm preparation on the day of oocyte retrieval]
  • Blastocyst rate and good-quality blastocysts rate [Time frame: Day 5 to Day 6 after ICSI]
  • Euploidy rate. [Time frame: Within 2 weeks after blastocyst biopsy]

Eligibility criteria

Inclusion criteria

  • Male partners aged ≥ 40 years
  • Semen analysis: volume ≥ 1.4 mL, sperm concentration ≥ 6 million/mL, progressive motility (PR) ≥ 20% after 3-5 days of abstinence.
  • Female partners with ≥ 5 mature (MII) oocytes retrieved.
  • Couples undergoing ICSI with PGT-A and elective single embryo transfer (eSET).
  • Willingness to participate and sign informed consent.

Exclusion criteria

  • Azoospermia, surgical sperm retrieval, or use of cryopreserved sperm.
  • Female uterine or ovarian conditions severely affecting IVF outcomes.
  • Use of donor sperm or donor oocytes

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Non-randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Vietnam · 1 center
  • Vietnam Military medical university — Hà Nội

Identifiers

NCT: NCT07605182 · MICEH-2026-01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗